<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Therapeutic approaches are not well established in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated response to <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> (CyA) in 19 cases with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> who were enrolled for the study [13 <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA), 5 <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), and 1 <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>)] </plain></SENT>
<SENT sid="2" pm="."><plain>Bone marrow was normocellular in ten, hypercellular in five, and hypocellular in four cases </plain></SENT>
<SENT sid="3" pm="."><plain>Fifteen patients were transfusion dependent and the rest were not transfusion dependent but with a <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> range of 6.4-8.8 g% with a mean of 7.4 g% </plain></SENT>
<SENT sid="4" pm="."><plain>CyA was given at a dose of 3-5 mg/kg per day </plain></SENT>
<SENT sid="5" pm="."><plain>A major response was observed in seven patients with RA, which was sustained on follow-up </plain></SENT>
<SENT sid="6" pm="."><plain>Four cases of RA showed minor response and two cases of RA did not respond to CyA therapy </plain></SENT>
<SENT sid="7" pm="."><plain>A minor response was also seen in one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> case, while one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> case that initially showed a major response relapsed on therapy </plain></SENT>
<SENT sid="8" pm="."><plain>The first effect of therapy was evident after a mean period of 2.5 months </plain></SENT>
<SENT sid="9" pm="."><plain>A rise in platelets and leukocyte count was seen in three and two cases, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>One case developed <z:hpo ids='HP_0000083'>renal failure</z:hpo> on therapy and later died of <z:mpath ids='MPATH_681'>septicemia</z:mpath> </plain></SENT>
<SENT sid="11" pm="."><plain>Response to CyA was independent of bone marrow cellularity </plain></SENT>
<SENT sid="12" pm="."><plain>CyA could be an effective mode of therapy in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> especially those having RA </plain></SENT>
</text></document>